These observations provide a strong rationale for stratification of lung adenocarcinoma patients harboring KRAS/KEAP- or KRAS/NFE2L2-mutant tumors as potential candidates to respond to glutaminase inhibition [249]. The gene discussed is KRAS; the disease is lung adenocarcinoma.